Targeting and vaccine durability are key for population-level impact and cost-effectiveness of a pox-protein HIV vaccine regimen in South Africa

BACKGROUND: RV144 is to date the only HIV vaccine trial to demonstrate efficacy, albeit rapidly waning over time. The HVTN 702 trial is currently evaluating in South Africa a similar vaccine formulation to that of RV144 for subtype C HIV with additional boosters (pox-protein regimen). Using a detail...

Descripción completa

Detalles Bibliográficos
Autores principales: Selinger, Christian, Bershteyn, Anna, Dimitrov, Dobromir T., Adamson, Blythe J.S., Revill, Paul, Hallett, Timothy B., Phillips, Andrew N., Bekker, Linda-Gail, Rees, Helen, Gray, Glenda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6684280/
https://www.ncbi.nlm.nih.gov/pubmed/30890385
http://dx.doi.org/10.1016/j.vaccine.2019.02.073

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6684280/
https://www.ncbi.nlm.nih.gov/pubmed/30890385
http://dx.doi.org/10.1016/j.vaccine.2019.02.073

Ejemplares similares